Last updated: April 22, 2026
Scope: “Suppliers” for dextroamphetamine sulfate in the US typically means (1) API manufacturers that produce the active pharmaceutical ingredient and (2) finished-dose or distribution partners that place branded or generic product on the market. Patent supply chains vary by dosage form and regulatory filings.
Who makes dextroamphetamine sulfate (API)?
The dextroamphetamine sulfate API supplier base is concentrated and largely aligned to pharmaceutical-grade controlled-substance manufacturing with DMF-linked access (where applicable). Publicly observable supplier lists most reliably surface through FDA drug labeling, generic product approvals, and controlled-substance registration (not through a single authoritative “supplier directory” that lists every API source).
Which finished-dose suppliers (US market) matter most?
In practice, market access comes through the NDC product holders (labeler of record) and their distribution channels, which include large US pharmaceutical wholesalers and specialty controlled-substance networks.
Major US product-labeler and distributor channels (finished doses)
Dextroamphetamine sulfate tablets and capsules are marketed as generics and in some cases branded forms historically. Labeler-of-record varies by strength (for example, 5 mg, 10 mg, 15 mg, 20 mg depending on product line) and by manufacturer at the time of approval and subsequent transfers.
Common supplier categories in this market:
- Generic manufacturers and their labeler-of-record entities for each specific NDC/strength
- Authorized wholesalers handling Schedule II controlled substances (standard US controlled-substance distribution)
- Pharmacy supply chains (retail and institutional) that source the finished dosage forms under DEA-controlled logistics
What procurement reality drives supplier selection?
Supply continuity for dextroamphetamine sulfate depends on:
- DEA Schedule II manufacturing and procurement logistics
- FDA CGMP compliance for the finished dosage form
- API supply stability tied to a limited number of qualified producers
- Ongoing NDC-specific availability (even when API supply exists, specific strengths can go out of stock)
Supplier selection checklist (actionable)
Procurement teams typically filter candidates using:
- Regulatory standing for the specific dosage form and strength (tablet vs capsule; immediate vs other release forms)
- NDC availability matching target SKU list
- Controlled-substance handling capability (DEA registrations and operational readiness)
- Batch-level documentation (COA readiness, impurity profile consistency, stability program)
- Supply assurance (lead time, historical fill rate, and contingency sourcing plans)
Market structure: where the concentration shows up
- API production: concentrated, with fewer qualified controlled-substance manufacturers.
- Finished product: more competitive at the generic labeler level, but availability still fluctuates by strength and manufacturing slot.
- Distribution: dominated by major wholesalers plus specialized channels that handle controlled substances.
Key implications for R&D and investment
- For formulation or scale-up work, vendor diligence should center on DMF linkage (if used), CGMP history, impurity controls, and change-management track record rather than broad “API supplier” claims.
- For commercialization or supply contracts, the critical unit is not “dextroamphetamine sulfate broadly,” but the exact NDC/strength with documented in-market continuity.
Key Takeaways
- Supplier visibility is NDC- and strength-specific for practical procurement; API sourcing is more opaque and concentrated.
- The market is shaped by Schedule II compliance, CGMP readiness, and batch documentation more than by generic “supplier lists.”
- Supply continuity risk is strength-specific, so contracts should anchor on SKUs and lead-time realities, not only on the API name.
FAQs
1) Are API suppliers publicly listed for dextroamphetamine sulfate?
Not in a single complete public directory; reliable identification typically comes from FDA-related documentation, labeler-of-record data by NDC, and controlled-substance manufacturing qualification signals.
2) Do API suppliers differ by tablet strength or dosage form?
Yes. Even when the API is the same chemical, finished-dose strengths and dosage forms can use different manufacturing sites and packaging supply chains, which affects labeler-of-record and availability.
3) Who are the “suppliers” in procurement terms?
Procurement usually treats the NDC labeler-of-record and their supply/distribution partners as the actionable suppliers, with API producers as upstream inputs.
4) What is the biggest operational risk in sourcing?
Schedule II logistics and strength-specific manufacturing constraints, which can cause intermittent shortages even when broader demand is stable.
5) How should a buyer qualify a supplier for this product?
Anchor qualification on CGMP compliance evidence, DEA-controlled logistics readiness, COA and batch documentation practices, and proven historical supply for the exact target NDC/strength.
References
[1] U.S. Food and Drug Administration. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Drug Enforcement Administration. Controlled Substances schedules. https://www.dea.gov/drug-information/drug-scheduling
